Golden
Oxford BioMedica

Oxford BioMedica

Gene and cell therapy group focused on developing life changing treatments for serious diseases.

All edits

Edits on 26 May 2019
Will Suter
Will Suter approved a suggestion from Golden's AI on 26 May 2019 12:33 am
Edits made to:
Article (+15/-15 characters)

Article

  • OXB-201 - gene therapy for wet AMD. Phase 1 clinical trialsclinical trials have been completed.
Will Suter
Will Suter approved a suggestion from Golden's AI on 26 May 2019 12:27 am
Edits made to:
Article (+20/-20 characters)

Article

Additionally, Oxford BioMedica has multiple partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard TherapeuticsOrchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products.

Edits on 23 May 2019
Golden AI
Golden AI edited on 23 May 2019 11:25 am
Edits made to:
Infobox (+1 properties)

Infobox

Location
Edits on 12 Feb 2019
Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 12 Feb 2019 10:43 pm
Edits made to:
Infobox (+1 properties)

Infobox

Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 12 Feb 2019 10:41 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 16 Jan 2019
Carla Faraguna
Carla Faraguna edited on 16 Jan 2019 8:47 pm
Edits made to:
Infobox (+1 properties)
Categories (+1 topics)

Infobox

Categories

Sameeha Sulaiman
Sameeha Sulaiman edited on 16 Jan 2019 12:31 pm
Edits made to:
Article (+88/-88 characters)

Article

Oxford BioMedica is a publicly traded, gene and cell therapy group based in OxfordOxford, Oxforshire, UK. The company and its subsidiaries (the "Group") have build a lentiviral delivery platform (LentiVector), which the Group leverages to develop in vivo and ex vivo products, both in-house and with partners. Its portfolio ranges across the areas of oncology, opthalmology, and CNS disorders.

...
  • AXO-LENTI-PD - gene therapy threatment for Parkinson's diseaseParkinson's disease. Phase 1/2 clinical studies in preparation. Partnered with Axovant.





Additionally, Oxford BioMedica has multiple partnerships, including with Novartis, BioverativBioverativ, SanofiSanofi, AxovantAxovant, Orchard Therapeutics, Boehringer IngelheimBoehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Imperial InnocationsInnovations, GC LabCell, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products.

Sameeha Sulaiman
Sameeha Sulaiman approved a suggestion from Golden's AI on 16 Jan 2019 12:28 pm
Edits made to:
Article (+17/-17 characters)

Article

  • SAR 422459 - gene therapy for Stargardt diseaseStargardt disease. Phase 2 clinical studies ongoing. Licensed to Sanofi.
Sameeha Sulaiman
Sameeha Sulaiman approved a suggestion from Golden's AI on 16 Jan 2019 12:28 pm
Edits made to:
Article (+14/-14 characters)

Article

  • SAR 421869 - gene therapy for Usher syndromeUsher syndrome type 1B. Phase 1/2a clinical trials ongoing. Licensed to Sanofi.
Sameeha Sulaiman
Sameeha Sulaiman approved a suggestion from Golden's AI on 16 Jan 2019 12:28 pm
Edits made to:
Article (+6/-6 characters)

Article

  • SAR 422459 - gene therapy for Stargardt disease. Phase 2 clinical studies ongoing. Licensed to SanofiSanofi.
Sameeha Sulaiman
Sameeha Sulaiman approved a suggestion from Golden's AI on 16 Jan 2019 12:28 pm
Edits made to:
Article (+13/-13 characters)

Article

Additionally, Oxford BioMedica has multiple partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innocations, GC LabCell, and Immune DesignImmune Design, through which it has long-term economic interests in other potential gene and cell therapy products.

Sameeha Sulaiman
Sameeha Sulaiman approved a suggestion from Golden's AI on 16 Jan 2019 12:28 pm
Edits made to:
Article (+8/-8 characters)

Article

Additionally, Oxford BioMedica has multiple partnerships, including with NovartisNovartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innocations, GC LabCell, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products.

Sameeha Sulaiman
Sameeha Sulaiman edited on 16 Jan 2019 12:26 pm
Edits made to:
Article (+382/-382 characters)

Article

Within its pipeline, Oxford BioMedica has several proprietary products, partnered products, and IP enabled and royalty bearing products. Its proprietary products, which would either be spun-out or licensed out, include:

  • OXB-202 - gene based treatment for corneal graft rejection. Phase 1/2 clinical studies are in preparation.
  • OXB-302 - gene based immunotherapy targeting a range of cancers. Pre-clinical studies are complete.
  • OXB-201 - gene therapy for wet AMD. Phase 1 clinical trials have been completed.
  • OXB-204 - in pre-clinical studies
  • OXB-208 - in pre-clinical studies
  • OXB-103 - in pre-clinical studies



The company's partnered products include:

  • AXO-LENTI-PD - gene therapy threatment for Parkinson's disease. Phase 1/2 clinical studies in preparation. Partnered with Axovant.
  • SAR 422459 - gene therapy for Stargardt disease. Phase 2 clinical studies ongoing. Licensed to Sanofi.
  • SAR 421869 - gene therapy for Usher syndrome type 1B. Phase 1/2a clinical trials ongoing. Licensed to Sanofi.
...

The company's partnered products include:

  • AXO-LENTI-PD - gene therapy threatment for Parkinson's disease. Phase 1/2 clinical studies in preparation. Partnered with Axovant.
  • SAR 422459 - gene therapy for Stargardt disease. Phase 2 clinical studies ongoing. Licensed to Sanofi.
  • SAR 421869 - gene therapy for Usher syndrome type 1B. Phase 1/2a clinical trials ongoing. Licensed to Sanofi.



Sameeha Sulaiman
Sameeha Sulaiman edited on 16 Jan 2019 12:24 pm
Edits made to:
Infobox (+3/-3 properties)
Description (+96 characters)
Article (+1723 characters)
People (+27 cells) (+470 characters)
Further reading (+8 cells) (+480 characters)
Topic thumbnail

Oxford BioMedica

Gene and cell therapy group focused on developing life changing treatments for serious diseases.

Article

Oxford BioMedica is a publicly traded, gene and cell therapy group based in Oxford, Oxforshire, UK. The company and its subsidiaries (the "Group") have build a lentiviral delivery platform (LentiVector), which the Group leverages to develop in vivo and ex vivo products, both in-house and with partners. Its portfolio ranges across the areas of oncology, opthalmology, and CNS disorders.



Within its pipeline, Oxford BioMedica has several proprietary products, partnered products, and IP enabled and royalty bearing products. Its proprietary products, which would either be spun-out or licensed out, include:

  • OXB-202 - gene based treatment for corneal graft rejection. Phase 1/2 clinical studies are in preparation.
  • OXB-302 - gene based immunotherapy targeting a range of cancers. Pre-clinical studies are complete.
  • OXB-201 - gene therapy for wet AMD. Phase 1 clinical trials have been completed.
  • OXB-204 - in pre-clinical studies
  • OXB-208 - in pre-clinical studies
  • OXB-103 - in pre-clinical studies



The company's partnered products include:

  • AXO-LENTI-PD - gene therapy threatment for Parkinson's disease. Phase 1/2 clinical studies in preparation. Partnered with Axovant.
  • SAR 422459 - gene therapy for Stargardt disease. Phase 2 clinical studies ongoing. Licensed to Sanofi.
  • SAR 421869 - gene therapy for Usher syndrome type 1B. Phase 1/2a clinical trials ongoing. Licensed to Sanofi.



Additionally, Oxford BioMedica has multiple partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innocations, GC LabCell, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products.



People

Name
Role
Related Golden topics

Andrew Heath

Deputy Chairman & Senior Independent Director



Dr. Lorenzo Tallarigo

Chairman



Heather Preston

Independent Non-Executive Director



Helen Stephenson-Ellis

Chief People Officer



James Miskin

Chief Technical Officer



Jason Slingsby

Chief Business Officer



John Dawson

CEO



Kyriacos Mitrophanous

Chief Scientific Officer



Lisa Giles

Chief Projects and Performance Officer



Martin Diggle

Non-Executive Director



Nick Page

COO



Stuart Henderson

Independent Non-Executive Director



Stuart Paynter

CFO



Further reading

Title
Author
Link
Type

Oxford BioMedica announces further capacity expansion with new facility

Oxford BioMedica plc

Web

Oxford BioMedica to capture 25-30% of lentiviral vector market by 2026, predicts CTO

biopharma-reporter.com

Web

Infobox

Edits on 14 Nov 2018
Jude Gomila"Approved suggestion from source: http://www.oxfordbiomedica.co.uk/"
Jude Gomila approved a suggestion from Golden's AI on 14 Nov 2018 2:46 am
Edits made to:
Infobox (+1 properties)
Edits on 9 Nov 2018
Jude Gomila"Approved suggestion from source: http://www.oxfordbiomedica.co.uk/"
Jude Gomila approved a suggestion from Golden's AI on 9 Nov 2018 11:34 pm
Edits made to:
Infobox (+1 properties)
Edits on 13 Sep 2018
Golden AI"Import structured data from Wikidata.org: https://www.wikidata.org/wiki/Q17019665"
Golden AI edited on 13 Sep 2018 6:12 pm
Edits made to:
Infobox (+3 properties)

Infobox

Headquarters location
Edits on 24 Jul 2018
Melanie Manipula
Melanie Manipula edited on 24 Jul 2018 10:47 pm
Edits on 21 Apr 2018
Melanie Manipula
Melanie Manipula edited on 21 Apr 2018 12:06 am
Edits made to:
Topic thumbnail

Oxford BioMedica

Gene and cell therapy group focused on developing life changing treatments for serious diseases.

Edits on 1 Jan 2017
Golden AI"Initial topic creation"
Golden AI created this topic on 1 Jan 2017 12:00 am
Edits made to:
Article
Topic thumbnail

 Oxford BioMedica

Gene and cell therapy group focused on developing life changing treatments for serious diseases.

No more activity to show.